Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
N/A
-122,964 Closed
0 $0
Q1 2023

May 15, 2023

SELL
N/A
-100,404 Reduced 81.65%
22,560 $74,000
Q4 2022

Aug 11, 2023

BUY
$3.08 - $4.05 $34,249 - $45,036
11,120 Added 9.94%
122,964 $407,000
Q4 2022

Feb 13, 2023

BUY
$3.08 - $4.05 $34,249 - $45,036
11,120 Added 9.94%
122,964 $407,000
Q3 2022

Aug 11, 2023

BUY
$2.97 - $4.83 $27,808 - $45,223
9,363 Added 9.14%
111,844 $350,000
Q3 2022

Nov 03, 2022

BUY
$2.97 - $4.83 $27,808 - $45,223
9,363 Added 9.14%
111,844 $340,000
Q2 2022

Aug 11, 2023

BUY
$2.54 - $4.52 $80,769 - $143,731
31,799 Added 44.99%
102,481 $336,000
Q2 2022

Aug 15, 2022

BUY
$2.54 - $4.52 $80,769 - $143,731
31,799 Added 44.99%
102,481 $338,000
Q1 2022

Aug 11, 2023

BUY
$3.81 - $10.77 $183,344 - $518,273
48,122 Added 213.31%
70,682 $322,000
Q1 2022

May 20, 2022

BUY
$3.81 - $10.77 $220,637 - $623,690
57,910 Added 453.41%
70,682 $343,000
Q4 2021

Feb 16, 2022

BUY
$6.35 - $47.04 $6,623 - $49,062
1,043 Added 8.89%
12,772 $99,000
Q3 2021

Nov 12, 2021

BUY
$20.88 - $56.08 $244,901 - $657,762
11,729 New
11,729 $495,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.